Gracell Biotechnologies Inc. (GRCL) - Total Liabilities
Based on the latest financial reports, Gracell Biotechnologies Inc. (GRCL) has total liabilities worth $268.86 Million USD as of September 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Gracell Biotechnologies Inc. (GRCL) equity growth momentum to track the company's year-over-year net asset growth rate.
Gracell Biotechnologies Inc. - Total Liabilities Trend (2018–2022)
This chart illustrates how Gracell Biotechnologies Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Gracell Biotechnologies Inc. Competitors by Total Liabilities
The table below lists competitors of Gracell Biotechnologies Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Henghe Mould Co Ltd
SHE:300539
|
China | CN¥615.27 Million |
|
SY HOLDINGS GROUP HD-01
F:9U0
|
Germany | €7.18 Billion |
|
CW Enerji SA
IS:CWENE
|
Turkey | TL20.29 Billion |
|
Beijing Strong Biotechnologies Inc
SHE:300406
|
China | CN¥1.30 Billion |
|
Preformed Line Products Company
NASDAQ:PLPC
|
USA | $178.28 Million |
|
Elopak AS
OL:ELO
|
Norway | Nkr708.73 Million |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
China | CN¥5.21 Billion |
|
TWO HARBORS INV. DL-0001
F:2H2
|
Germany | €9.07 Billion |
Liability Composition Analysis (2018–2022)
This chart breaks down Gracell Biotechnologies Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GRCL company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gracell Biotechnologies Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gracell Biotechnologies Inc. (2018–2022)
The table below shows the annual total liabilities of Gracell Biotechnologies Inc. from 2018 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $280.51 Million | +20.51% |
| 2021-12-31 | $232.77 Million | +60.21% |
| 2020-12-31 | $145.29 Million | -7.38% |
| 2019-12-31 | $156.86 Million | +7.34% |
| 2018-12-31 | $146.13 Million | -- |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more